These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

538 related items for PubMed ID: 19436235

  • 1. Increased levels of both carbohydrate antigen 19-9 and duke pancreatic monoclonal antigen type 2 reflect postoperative prognosis in patients with pancreatic carcinoma.
    Shibata K, Iwaki K, Kai S, Ohta M, Kitano S.
    Pancreas; 2009 Aug; 38(6):619-24. PubMed ID: 19436235
    [Abstract] [Full Text] [Related]

  • 2. Undetectable preoperative levels of serum CA 19-9 correlate with improved survival for patients with resectable pancreatic adenocarcinoma.
    Berger AC, Meszoely IM, Ross EA, Watson JC, Hoffman JP.
    Ann Surg Oncol; 2004 Jul; 11(7):644-9. PubMed ID: 15197014
    [Abstract] [Full Text] [Related]

  • 3. Comparison of the prognostic impact of pre- and post-operative CA19-9, SPan-1, and DUPAN-II levels in patients with pancreatic carcinoma.
    Kondo N, Murakami Y, Uemura K, Nakagawa N, Takahashi S, Ohge H, Sueda T.
    Pancreatology; 2017 Jul; 17(1):95-102. PubMed ID: 27746094
    [Abstract] [Full Text] [Related]

  • 4. Preoperative serum CA19-9 and dissected peripancreatic tissue margin as determiners of long-term survival in pancreatic cancer.
    Waraya M, Yamashita K, Katagiri H, Ishii K, Takahashi Y, Furuta K, Watanabe M.
    Ann Surg Oncol; 2009 May; 16(5):1231-40. PubMed ID: 19263172
    [Abstract] [Full Text] [Related]

  • 5. Serum markers in patients with resectable pancreatic adenocarcinoma: macrophage inhibitory cytokine 1 versus CA19-9.
    Koopmann J, Rosenzweig CN, Zhang Z, Canto MI, Brown DA, Hunter M, Yeo C, Chan DW, Breit SN, Goggins M.
    Clin Cancer Res; 2006 Jan 15; 12(2):442-6. PubMed ID: 16428484
    [Abstract] [Full Text] [Related]

  • 6. Clinical significance of serum carbohydrate antigen 19.9 and duke pancreatic monoclonal antigen type 2 for the prediction of hematogenous metastases in patients with pancreatic ducal adenocarcinoma.
    Kurahara H, Maemura K, Mataki Y, Sakoda M, Iino S, Arigami T, Mori S, Ueno S, Shinchi H, Takao S, Natsugoe S.
    Pancreatology; 2016 Jan 15; 16(6):1051-1056. PubMed ID: 27693096
    [Abstract] [Full Text] [Related]

  • 7. CA19-9 in potentially resectable pancreatic cancer: perspective to adjust surgical and perioperative therapy.
    Hartwig W, Strobel O, Hinz U, Fritz S, Hackert T, Roth C, Büchler MW, Werner J.
    Ann Surg Oncol; 2013 Jul 15; 20(7):2188-96. PubMed ID: 23247983
    [Abstract] [Full Text] [Related]

  • 8. Prognostic impact of perioperative serum CA 19-9 levels in patients with resectable pancreatic cancer.
    Kondo N, Murakami Y, Uemura K, Hayashidani Y, Sudo T, Hashimoto Y, Nakashima A, Sakabe R, Shigemoto N, Kato Y, Ohge H, Sueda T.
    Ann Surg Oncol; 2010 Sep 15; 17(9):2321-9. PubMed ID: 20336387
    [Abstract] [Full Text] [Related]

  • 9. The clinical value of serum CEA, CA19-9, and CA242 in the diagnosis and prognosis of pancreatic cancer.
    Ni XG, Bai XF, Mao YL, Shao YF, Wu JX, Shan Y, Wang CF, Wang J, Tian YT, Liu Q, Xu DK, Zhao P.
    Eur J Surg Oncol; 2005 Mar 15; 31(2):164-9. PubMed ID: 15698733
    [Abstract] [Full Text] [Related]

  • 10. Preoperative carbohydrate antigen 19-9 is most predictive of malignancy in older jaundiced patients undergoing pancreatic resection.
    Bloomston M, Bekaii-Saab TS, Kosuri K, Cowgill SM, Melvin WS, Ellison EC, Muscarella P.
    Pancreas; 2006 Oct 15; 33(3):246-9. PubMed ID: 17003645
    [Abstract] [Full Text] [Related]

  • 11. The use of adjusted preoperative CA 19-9 to predict the recurrence of resectable pancreatic cancer.
    Kang CM, Kim JY, Choi GH, Kim KS, Choi JS, Lee WJ, Kim BR.
    J Surg Res; 2007 Jun 01; 140(1):31-5. PubMed ID: 17418869
    [Abstract] [Full Text] [Related]

  • 12. Prognostic Role of Preoperative Duke Pancreatic Monoclonal Antigen Type 2 Levels in Patients with Pancreatic Cancer.
    Shimizu Y, Sugiura T, Ashida R, Ohgi K, Yamada M, Otsuka S, Uesaka K.
    Ann Surg Oncol; 2023 Sep 01; 30(9):5792-5800. PubMed ID: 37248377
    [Abstract] [Full Text] [Related]

  • 13. Preoperative serum carcinoembryonic antigen and carbohydrate antigen 19-9 levels for the evaluation of curability and resectability in patients with pancreatic adenocarcinoma.
    Fujioka S, Misawa T, Okamoto T, Gocho T, Futagawa Y, Ishida Y, Yanaga K.
    J Hepatobiliary Pancreat Surg; 2007 Sep 01; 14(6):539-44. PubMed ID: 18040617
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Is it reasonable to add preoperative serum level of CEA and CA19-9 to staging for colorectal cancer?
    Chen CC, Yang SH, Lin JK, Lin TC, Chen WS, Jiang JK, Wang HS, Chang SC.
    J Surg Res; 2005 Apr 01; 124(2):169-74. PubMed ID: 15820244
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Elevated chromogranin A (CgA) serum levels in the patients with advanced pancreatic cancer.
    Malaguarnera M, Cristaldi E, Cammalleri L, Colonna V, Lipari H, Capici A, Cavallaro A, Beretta M, Alessandria I, Luca S, Motta M.
    Arch Gerontol Geriatr; 2009 Apr 01; 48(2):213-7. PubMed ID: 18329114
    [Abstract] [Full Text] [Related]

  • 18. Preoperative serum level of CA19-9 predicts recurrence after curative surgery in node-negative colorectal cancer patients.
    Nakagoe T, Sawai T, Tsuji T, Jibiki MA, Nanashima A, Yamaguchi H, Yasutake T, Ayabe H, Arisawa K.
    Hepatogastroenterology; 2003 Apr 01; 50(51):696-9. PubMed ID: 12828063
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Expression of tumor-associated carbohydrate antigens correlates with hepatic metastasis of pancreatic cancer: clinical and experimental studies.
    Takamori H, Hiraoka T, Yamamoto T.
    Hepatogastroenterology; 1996 Apr 01; 43(9):748-55. PubMed ID: 8799425
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 27.